Thrombotic thrombocytopenic purpura complicated with hypereosinophilic syndrome

Internal Medicine

Volumn 48, Issue 18, 2009, Pages 1687-1690

  Ohguchi, Hiroto ^a,b   Sugawara, Tomohiro ^b   Harigae, Hideo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Osaki Citizen Hospital   (Japan)

Author keywords

Eosinophilia; Hypereosinophilic syndrome; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Indexed keywords

CORTICOSTEROID;

AGED; ARTICLE; CASE REPORT; FEMALE; HUMAN; HYPEREOSINOPHILIC SYNDROME; LEUKOCYTE COUNT; NEUROLOGIC DISEASE; PLASMAPHERESIS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; AGED; AGED, 80 AND OVER; FEMALE; GLUCOCORTICOIDS; HUMANS; HYPEREOSINOPHILIC SYNDROME; PLASMAPHERESIS; PREDNISOLONE; PROTEASE INHIBITORS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 70349507137     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2282     Document Type: Article

References (18)

1. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 112: 11-18, 2008.
2. Fujimura Y, Matsumoto M, Yagi H, Yoshioka A, Matsui T, Titani K. Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. Int J Hematol 75: 25-34, 2002.
3. Wilkins HJ, Crane MM, Copeland K, Williams WV. Hypereosinophilic syndrome: an update. Am J Hematol 80: 148-157, 2005.
4. Liapis H, Ho AK, Brown D, Mindel G, Gleich G. Thrombotic microangiopathy associated with the hypereosinophilic syndrome. Kidney Int 67: 1806-1811, 2005.
5. Al Aly Z, Philoctete Ashley JM, Gellens ME, Gonzalez EA. Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence? Am J Kidney Dis 45: 762-768, 2005.
6. Bain B, Vardiman JW, Pierre R, Brunning RD, Imbert M, Flandrin G. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 3rd ed. Jaffe ES, Harris NL, Stein H, Vardiman JW, Eds. IARC Press, Lyon, 2001: 29-31.
7. Ogbogu PU, Rosing DR, Horne MK 3rd. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 27: 457-475, 2007.
8. Venge P, Dahl R, Hallgren R. Enhancement of factor XII dependent reactions by eosinophil cationic protein. Thromb Res 14: 641-649, 1979.
9. Rohrbach MS, Wheatley CL, Slifman NR, Gleich GJ. Activation of platelets by eosinophil granule proteins. J Exp Med 172: 1271-1274, 1990.
10. Slungaard A, Vercellotti GM, Tran T, Gleich GJ, Key NS. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest 91: 1721-1730, 1993.
11. Mukai HY, Ninomiya H, Ohtani K, Nagasawa T, Abe T. Major basic protein binding to thrombomodulin potentially contributes to the thrombosis in patients with eosinophilia. Br J Haematol 90: 892-899, 1995.
12. Wang JG, Mahmud SA, Thompson JA, Geng JG, Key NS, Slungaard A. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood 107: 558-565, 2006.
13. Fitzpatrick JE, Johnson C, Simon P, Owenby J. Cutaneous microthrombi: a histologic clue to the diagnosis of hypereosinophilic syndrome. Am J Dermatopathol 9: 419-422, 1987.
14. Kojima K, Sasaki T. Veno-occlusive disease in hypereosinophilic syndrome. Intern Med 34: 1194-1197, 1995.
15. Yamada T, Shinohara K, Katsuki K. A case of idiopathic hypereosinophilic syndrome complicated with disseminated intravascular coagulation. Am J Hematol 59: 100-101, 1998.
16. Johnston AM, Woodcock BE. Acute aortic thrombosis despite anticoagulant therapy in idiopathic hypereosinophilic syndrome. J R Soc Med 91: 492-493, 1998.
17. Numagami Y, Tomita T, Murakami K, Masaki I, Kubo K, Michiharu N. Sinus thrombosis in idiopathic hypereosinophilic syndrome causing fatal cerebral haemorrhage. J Clin Neurosci 15: 585-587, 2008.
18. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201-1214, 2003.